MeiraGTx Holdings plc Accounts Receivable, Related Parties, Current
MeiraGTx Holdings plc (MGTX) had Accounts Receivable, Related Parties, Current of $36.30 million as of 2023-03-31, per its 10-Q filed 2023-05-11.
Discontinued › Notes
us-gaap:AccountsReceivableRelatedPartiesCurrent · last filed 2023-05-11
- 2023-03-31: Accounts Receivable, Related Parties, Current $36.30M.
- 2022-12-31: Accounts Receivable, Related Parties, Current $21.33M.
- 2022-09-30: Accounts Receivable, Related Parties, Current $23.70M.
- 2022-06-30: Accounts Receivable, Related Parties, Current $15.94M.
| Period end | Accounts Receivable, Related Parties, Current | Accounts Receivable, Related Parties, Current as first filed |
|---|---|---|
| 2023-03-31 | $36.30M 10-Q · filed 2023-05-11 | |
| 2022-12-31 | $21.33M 10-Q · filed 2023-05-11 | |
| 2022-09-30 | $23.70M 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $15.94M 10-Q · filed 2022-08-11 | |
| 2022-03-31 | $13.08M 10-Q · filed 2022-05-12 | |
| 2021-12-31 | $22.38M 10-K · filed 2023-03-14 | |
| 2021-09-30 | $16.77M 10-Q · filed 2021-11-10 | |
| 2021-06-30 | $17.97M 10-Q · filed 2021-08-11 | |
| 2021-03-31 | $12.02M 10-Q · filed 2021-05-11 | |
| 2020-12-31 | $38.48M 10-K · filed 2022-03-10 | $38.48M 10-K · filed 2021-03-11 |
| 2020-09-30 | $26.64M 10-Q · filed 2020-11-05 | |
| 2020-06-30 | $24.43M 10-Q · filed 2020-08-06 | |
| 2020-03-31 | $27.98M 10-Q · filed 2020-05-07 | |
| 2019-12-31 | $23.34M 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |